| 0 (0%) | 04-19 11:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.62 | 1-year : | 3.06 |
| Resists | First : | 2.25 | Second : | 2.62 |
| Pivot price | 2.08  |
|||
| Supports | First : | 1.92 | Second : | 1.73 |
| MAs | MA(5) : | 2.04 |
MA(20) : | 2.05 |
| MA(100) : | 1.89 |
MA(250) : | 1.57 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 30.6 |
D(3) : | 38.9 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.25 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNN ] has closed above bottom band by 22.3%. Bollinger Bands are 5.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.11 | 2.11 - 2.12 |
| Low: | 1.94 - 1.96 | 1.96 - 1.98 |
| Close: | 1.99 - 2.02 | 2.02 - 2.04 |
Thu, 29 Feb 2024
Life beyond Provenge: Dendreon enters CDMO world - BioProcess Insider - BioProcess Insider
Fri, 16 Jun 2023
Toronto restaurant in high turnover location has permanently closed - blogTO
Thu, 18 Nov 2021
Grant Hill Partners With Dendreon Pharmaceuticals To 'Educate Black Men About The Burden Of Prostate Cancer' - AfroTech
Wed, 11 Aug 2021
Dendreon And Shoreline Enter CMC Agreement - Contract Pharma
Tue, 29 Jun 2021
Second Path: Dendreon Seeks Growth beyond Provenge - Genetic Engineering & Biotechnology News
Thu, 17 Jun 2021
Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partners - FiercePharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 873 (M) |
| Shares Float | 884 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 44.2 (%) |
| Shares Short | 38,060 (K) |
| Shares Short P.Month | 34,820 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.62 |
| Profit Margin | 485.9 % |
| Operating Margin | -376 % |
| Return on Assets (ttm) | -4.7 % |
| Return on Equity (ttm) | 10.3 % |
| Qtrly Rev. Growth | -9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | 40.2 |
| PEG Ratio | 0 |
| Price to Book value | 3.19 |
| Price to Sales | 170 |
| Price to Cash Flow | -52.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|